Customized Precision Antibiotics: CRISPR Technology Selectively Eliminates Resistance Genes
Background
Conventional antibiotic prescriptions indiscriminately kill not only specific bacteria but also beneficial microbial communities in the human body. This disrupts the gut microbial ecosystem and, in the long term, induces antimicrobial resistance (AMR), exacerbating the emergence of superbugs that are untreatable. To overcome AMR, which threatens global health security and economic stability, there is a need to establish a precise treatment strategy that differs from existing chemical drugs.
Traditional antibiotic development has focused on finding new target proteins or modifying the chemical structure of existing drugs. However, as the rate of bacterial evolution outpaces the rate of drug development, the lifespan of new drugs is becoming increasingly shorter. While the types of antibiotics used clinically are limited, the spread of multidrug-resistant bacteria is accelerating, depleting the means of response in the medical field. Therefore, it is necessary to develop a precision weapon that selectively destroys specific resistance genes acquired by bacteria, thereby preventing the spread of resistance and preserving beneficial microorganisms.
Key Findings
Recent research teams have demonstrated a precision antibiotic technology that selectively removes resistance genes from target bacteria while preserving beneficial bacteria using the CRISPR-Cas gene editing system. This study was conducted on ESKAPE pathogens, which are major causes of nosocomial infections. ESKAPE pathogens include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, which are representative multidrug-resistant bacteria.
The researchers used CRISPR-Cas9 to precisely target and eliminate the tetracycline resistance gene (tetM) and the erythromycin resistance gene (ermB) in the bacterial genome. As a result, the resistance rate of strains carrying these genes was significantly reduced. In particular, they successfully targeted the highly transmissible colistin resistance gene (mcr-1) and plasmid-mediated mobile genetic elements, thereby blocking the pathway by which resistance genes are horizontally transferred to other strains. This demonstrates that the function of mobile genetic elements, which transmit resistance by transferring to surrounding strains even after the parent bacteria die, can be physically inhibited.
However, the same efficiency was not observed in all bacteria. In some bacterial strains, the activity of the gene editing system was reduced due to the diversity and genetic variation of the CRISPR loci they possessed. It was also revealed that the bacteria recognize the externally introduced gene editing system as their own defense mechanism and decompose it, or that mutations occur in the target sequence, preventing the gene editing system from binding. This implies that patient-specific or strain-specific design is required.
Significance and Prospects
CRISPR-based precision antibiotics can directly recognize specific base sequences of bacteria, thereby eliminating the mechanism of resistance acquisition. Unlike conventional antibiotics that destroy the entire microbial ecosystem, it eliminates only the target strains, preventing side effects caused by microbiome disruption. In particular, it is expected to be useful for treating elderly or immunocompromised patients, as it can significantly reduce the risk of secondary infections such as antibiotic-induced colitis.
However, there are still challenges to be overcome before it can be applied to actual clinical practice. It is essential to optimize the system for safely and efficiently delivering the gene editing system into bacterial cells. Fusion with next-generation delivery technologies such as modified bacteriophages or lipid nanoparticles is necessary. In addition, it is necessary to minimize off-target effects, in which non-target genes are incorrectly cleaved, and to verify the in vivo stability of the therapeutic agent. The establishment of biosafety standards that meet the requirements of a new type of bio-pharmaceutical and the establishment of regulatory guidelines by regulatory agencies will accelerate the commercialization of the therapeutic agent.
Antimicrobial resistance (AMR) has diminished the effectiveness of present antibiotics, posing a huge threat to global community health and economic stability. This study investigates the CRISPR-Cas framework's potential as a cutting-edge tactic to fight antimicrobial resistance. Current applications, limitations, and prospective future uses are analyzed. CRISPR antimicrobial strategies, which bring together the latest developments in gene-targeting strategies, engineered delivery platforms, and translational applications to fight multidrug-resistant pathogens. CRISPR technology is different from traditional antimicrobial treatments that target general antimicrobial resistance genes, instead allowing targets to be eliminated specifically by sequence, while retaining beneficial microbial communities, which has the potential to be a transformative precision antimicrobial treatment. Nevertheless, there is still a need for optimization of delivery systems, specificity of targets, biosafety, and regulations to ensure successful clinical translation, especially given their amazing advances. Recent research confirms that CRISPR-based mechanisms also affect different bacterial species, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species, playing a key function in averting the emergence of resistance genes in these bacteria. Changes to CRISPR loci affect how resistance genes are targeted in ESKAPE pathogens, and CRISPR-Cas9 successfully lowers resistance by focusing on genes like tetM and ermB. A promising application of CRISPR-Cas systems in combating antimicrobial resistance (AMR) is the precise targeting of plasmid-borne mcr-1 resistance genes and other mobile genetic elements that facilitate the dissemination of colistin resistance. But the efficiency of CRISPR-Cas is diminished in some bacterial strains due to variations in their CRISPR loci. Enhancing transformation appr
The commercialization of this technology will open new avenues for the treatment of multidrug-resistant bacterial infections in intensive care units. A scenario in which a gene editing system tailored to the genetic information of individual bacteria is designed and precisely administered to patients who cannot be treated with existing antibiotics will become a reality. For example, by administering a CRISPR therapeutic agent that targets only the mcr-1 gene to a patient infected with colistin-resistant bacteria, it is possible to selectively eliminate the resistant bacteria while minimizing the loss of beneficial bacteria in the patient's gut. In terms of the pharmaceutical industry, it is expected that a sustainable antibiotic platform that does not cause concerns about the destruction of the microbial ecosystem can be developed, securing a new high-value pipeline.